Invited commentary: Timing of mechanically assisted circulatory support

The Journal of Heart and Lung Transplantation
Invited commentary: Timing of mechanically assisted circulatory support
The global estimate is that 26 million patients suffer from heart failure (HF), a condition with profound morbidity and mortality.1 Over time, sometimes rapidly, patients progress to advanced stages of HF. Estimation of the prevalence of advanced HF varies from 6-25% of patients with established HF.2 Other than cardiac transplantation, only mechanical circulatory support devices provide life prolongation in pump failure unresponsive to optimal medical therapy (OMM).3 The paper by Ambardekar et al attempts to define the sweet spot of the severity of the disease process when left ventricular assist device (LVAD) should be considered4 and they do so by comparing patients with non-inotropic therapy dependent advanced heart failure (INTERMACS-4-7) that receive an LVAD to a group of patients treated with OMM.
Source: The Journal of Heart and Lung Transplantation

Geef een reactie

Het e-mailadres wordt niet gepubliceerd. Vereiste velden zijn gemarkeerd met *